News

Mr Davis brings over 25 years of experience in global healthcare and medical devices markets and over 14 of those in the ophthalmic arena to Paradigm Medical Industries.

Under the terms of the agreement, Lantheus acquired the US, including Puerto Rico, Canadian, and Australian rights to MS-325 from Epix. Epix will continue to own European and

Pfizer has discontinued the SUN 1107 Phase III study of Sutent in advanced breast cancer based on statistical assessment for futility. SUN 1107 evaluated single-agent sunitinib versus single-agent

Participating in the company’s second funding round were Emergent Medical Partners, Saints Capital, Mitsubishi International, and Fog City Fund plus several private individuals. Jill Anderson, president and CEO

According to Covance, the new offices and expanded facilities in Latin America will help the company expedite the execution of clinical studies with a full range of services,

From 1990-1997, Mr Moran served as president of Synthes Spine, a division of Synthes (USA) that designs, manufactures and distributes implants and instruments for spinal disorders. Mr Moran

This study involves the prospective collection of samples from well-characterized Parkinson’s patients combined with Arrayit’s new H25K microarray technology. The first experiments have enabled rapid and efficient sample

Dr Carter takes over from Robert Bertoldi, who was serving as interim CEO. Mr Bertoldi will continue in his WellGen board position and as president and CFO of

Gilead Sciences, a biopharmaceutical company, has reported that DAR-311, a Phase III clinical trial evaluating the company’s endothelin receptor antagonist darusentan for the treatment of resistant hypertension, met